NT5C2

Purine 5-prime-nucleotidase (EC 3.1.3.5) preferentially hydrolyzes inosine 5-prime-monophosphate (IMP) and other purine nucleotides, and is allosterically activated by various compounds, including ATP. The enzyme is exclusively located in the cytoplasmic matrix of cells and may have a critical role in the maintenance of a constant composition of intracellular purine/pyrimidine nucleotides in cooperation with other nucleotidases.[supplied by OMIM

Full Name

5'-nucleotidase, cytosolic II

Function

Broad specificity cytosolic 5'-nucleotidase that catalyzes the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates (PubMed:1659319, PubMed:9371705, PubMed:10092873, PubMed:12907246).
In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine (PubMed:1659319, PubMed:9371705).
Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP (PubMed:1659319, PubMed:9371705, PubMed:10092873, PubMed:12907246).
Could also catalyze the transfer of phosphates from pyrimidine monophosphates but with lower efficiency (PubMed:1659319, PubMed:9371705).
Through these activities regulates the purine nucleoside/nucleotide pools within the cell (PubMed:1659319, PubMed:9371705, PubMed:10092873, PubMed:12907246).

Biological Process

Adenosine metabolic processManual Assertion Based On ExperimentIBA:GO_Central
Allantoin metabolic processManual Assertion Based On ExperimentIDA:MGI
dGMP metabolic processManual Assertion Based On ExperimentIDA:UniProtKB
GMP metabolic processManual Assertion Based On ExperimentIDA:UniProtKB
IMP catabolic processManual Assertion Based On ExperimentIDA:MGI
IMP metabolic processManual Assertion Based On ExperimentIDA:UniProtKB
Nucleotide phosphorylationManual Assertion Based On ExperimentIDA:UniProtKB

Cellular Location

Cytoplasm, cytosol

Involvement in disease

Spastic paraplegia 45, autosomal recessive (SPG45):
A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG45 patients manifest mental retardation, contractures and learning disability.